CORRECTION**Antiangiogenic therapy: impact on invasion, disease progression, and metastasis**

John M. L. Ebos & Robert S. Kerbel

Nat. Rev. Clin. Oncol. 8, 210–221 (2011); doi:10.1038/nrclinonc.2011.21

In the Review article published in the April issue of *Nature Reviews Clinical Oncology* there were errors in the clinical data presented in Tables 1 and 2. In addition, the primary end point of the adjuvant AVANT and NSABP-C-08 trials should have been disease-free survival (DFS) instead of progression-free survival (PFS). The errors have been corrected for the HTML and PDF versions of the article.